Medical Confidentiality. The Employer respects the confidentiality of employee medical records. Under normal circumstances, the Employer also recognizes the entitlement of its employees to their own choice of physician.
Medical Confidentiality. The City respects the confidentiality of employee medical records. Under normal circumstances, the City also recognizes the entitlement of its employees to their own choice of physician.
Medical Confidentiality. NAMM agrees to comply with applicable federal, state and local laws for handling confidential medical information and shall take all appropriate and reasonable action in developing technological and contractual methods of maintaining confidentiality for any medical or other confidential information converted to electronic data.
Medical Confidentiality. In accordance with the requirements of HIPAA and FERPA, the University shall respect the highly confidential status of all SWs’ medical records maintained by the University, including those that contain information about their transgender status (such as the sex they were assigned at birth).
Medical Confidentiality. The Parties shall adhere to the principles of medical confidentiality in relation to Clinical Trial Subjects. The Medical Records and any other Personal Data of a Clinical Trial Subject shall not be disclosed to the Sponsor or CRO by the Clinical Organisation, save where necessary in any of the following circumstances:
Medical Confidentiality. The Parties agree to adhere to the principles of medical confidentiality in relation to Clinical Trial Subjects involved in the Clinical Trial. Sensitive personal data (as defined in the Data Protection Act 1998) shall not be disclosed to the Sponsor by the Practice or the Investigator save where this is required to satisfy the requirements of the Protocol or for the purpose of monitoring or adverse event reporting, or in relation to a claim or proceeding brought by the Clinical Trial Subject in connection with the Clinical Trial. The Sponsor shall not disclose the identity of Clinical Trial Subjects to third parties without prior written consent of the Clinical Trial Subject, except in accordance with the provisions of the Data Protection Act 1998 and the principles set out in the Code of Practice on Protecting the Confidentiality of service user information (Department of Health, Social Services and Public Safety, January 2012), unless in relation to a claim or proceeding brought by the Clinical Trial Subject in connection with the Clinical Trial.
Medical Confidentiality. The Parties agree to adhere to the principles of medical confidentiality in relation to Clinical Trial Subjects involved in the Clinical Trial. Personal data (as defined in the Data Protection Act 1998) shall not be disclosed to the Sponsor by the Practice or the Investigator save where this is required to satisfy the requirements of the Protocol or for the purpose of monitoring or adverse event reporting, or in relation to a claim or proceeding brought by the Clinical Trial Subject in connection with the Clinical Trial. The Sponsor shall not disclose the identity of Clinical Trial Subjects to third parties without prior written consent of the Clinical Trial Subject, except in accordance with the provisions of the Data Protection Act 1998 and the principles set out in the NHS Scotland Code of Practice on Protecting Patient Confidentiality (August 2003), unless in relation to a claim or proceeding brought by the Clinical Trial Subject in connection with the Clinical Trial.
Medical Confidentiality. 6.6.1. The Parties agree to adhere to the local principles of medical confidentiality in relation to patients involved in the Project. Personal data (as defined in the Data protection Act 1998 or local laws) shall not be disclosed save where this is required directly or indirectly to satisfy the requirements of the Project or for the purpose of monitoring or Adverse Event reporting and subject always to compliance with the Data Protection Act 1998 and/or local laws on medical confidentiality.
